Aaron Barnes, DO
Family Medicine · Lexington, KYNPI 1558892877
Payments from drug & device makers
Across 437 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Pfizer$1K
- Lilly USA, LLC$858
- Novo Nordisk$778
- Boehringer Ingelheim$569
- GSK$388
- plus $2K from 30 others
What the payments were for
- Food & beverage$8,165100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 100 | $2,238 |
| Pfizer | 73 | $1,014 |
| Lilly USA, LLC | 49 | $858 |
| Novo Nordisk | 37 | $778 |
| Boehringer Ingelheim | 23 | $569 |
| GSK | 26 | $388 |
| Biohaven Pharmaceuticals, Inc. | 15 | $370 |
| Bayer | 5 | $183 |
| Phathom Pharmaceuticals, Inc. | 12 | $174 |
| Merck | 11 | $170 |
| Abbott | 8 | $156 |
| Novartis | 9 | $133 |
| AstraZeneca | 7 | $120 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $110 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $85 |
| Gilead | 5 | $84 |
| Amgen | 5 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $73 |
| Dynavax Technologies Corporation | 4 | $62 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $57 |
| Ultragenyx Pharmaceutical Inc. | 3 | $56 |
| Xeris Pharmaceuticals, Inc. | 2 | $46 |
| Johnson & Johnson | 3 | $44 |
| Axsome Therapeutics, Inc. | 2 | $38 |
| Kowa Pharmaceuticals America, Inc. | 3 | $36 |
| Astellas Pharma US Inc | 2 | $34 |
| Exact Sciences | 2 | $33 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Almatica Pharma LLC | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Inogen, Inc. | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $12 |
| IBSA Pharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,165 in reported general payments places this provider in the 90th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 67 | $80,036 |
| EliquisApixaban | 72 | $69,391 |
| JardianceEmpagliflozin | 42 | $51,654 |
| RybelsusSemaglutide | 17 | $34,181 |
| XareltoRivaroxaban | 21 | $20,218 |
| FarxigaDapagliflozin Propanediol | 14 | $19,158 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $18,960 |
| LinzessLinaclotide | 21 | $17,480 |
| MounjaroTirzepatide | 13 | $12,695 |
| MyrbetriqMirabegron | 21 | $12,411 |
| Emgality PenGalcanezumab-Gnlm | 14 | $10,392 |
| TrintellixVortioxetine Hydrobromide | 11 | $7,706 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $7,642 |
| Solifenacin Succinate | 21 | $2,934 |
| Gabapentin | 119 | $2,459 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $778 | $114,21784 claims |
| PfizerEliquis | $1,014 | $69,39172 claims |
| Boehringer IngelheimJardiance | $569 | $51,65442 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $388 | $26,60239 claims |
| Johnson & JohnsonXarelto | $44 | $20,21821 claims |
| AbbVieLinzess, Synthroid | $2,238 | $19,54867 claims |
| AstraZenecaFarxiga | $120 | $19,15814 claims |
| Lilly USA, LLCMounjaro | $858 | $12,69513 claims |
| Astellas Pharma US IncMyrbetriq | $34 | $12,41121 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $73 | $7,70611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Lexington
- Barbara Fleming-PhillipsLexington$1.4M
- John RichardLexington$226K
- Eleida Tur OlivaLexington$113K
- Susan NeilLexington$18K
- Brian SmithVersailles$7.7M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.